Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors

Abstract The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors show survival benefits in ovarian cancer patients with BRCA1/2 mutation or homologous recombination (HR) deficiency, but only limited efficacy in HR-proficient ones. Another drug, arsenic trioxide (ATO) or arsenic drug (RIF...

Full description

Bibliographic Details
Main Authors: Junfen Xu, Yuanming Shen, Conghui Wang, Sangsang Tang, Shiyuan Hong, Weiguo Lu, Xing Xie, Xiaodong Cheng
Format: Article
Language:English
Published: Nature Publishing Group 2021-09-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-021-00638-2

Similar Items

Similar Items